3-13 -06

IFW/8

OIPE 420	_				1
MAR 1 0 2006	U.S	. Patent and 1	Trademark Office:	PTO/SB/21 (0 e through 07/31/2006, OMB 0651, U.S. DEPARTMENT OF COMME	-0 03 i ERCE
Short Disman-bwork Reduction Act of 1995, no berso	Application Number	10/601,24		it displays a valid OMB control nu	mber.
TRANSMITTAL	Filing Date		 		\longrightarrow
FORM	First Named Inventor	06/20/200			
FORIVI	Art Unit	Phillip Da	n Cook		
	Examiner Name	1635			
(to be used for all correspondence after initial filing)		Janet Epp	os Ford		
Total Number of Pages in This Submission	Attorney Docket Number	ISIS-5213	3		
. ENC	LOSURES (Check a	li that appl			$\overline{}$
(Check a	п спас аррі	-	Allowance Communication to	TC
Fee Transmittal Form	Drawing(s)			Amorrance Communication to	'
Fee Attached	Licensing-related Papers			al Communication to Board peals and Interferences	ŀ
Amendment/Reply	Petition		Appe	al Communication to TC eal Notice, Brief, Reply Brief)	
	Petition to Convert to a			rietary Information	į
After Final	Provisional Application Power of Attorney, Revocati	on			
Affidavits/declaration(s)	Change of Correspondence	Address		s Letter r Enclosure(s) (please Identify	.
Extension of Time Request	Terminal Disclaimer		Other below		' I
Express Abandonment Request	Request for Refund				
Information Disclosure Statement	CD, Number of CD(s)				
iniomation disclosure Statement					1
Contified Copy of Priority	Landscape Table on C	U	<u></u>		
Certified Copy of Priority Document(s)	arks				
Reply to Missing Parts/					
Incomplete Application Reply to Missing Parts					
under 37 CFR 1.52 or 1.53					I
					Ī
SIGNATURE (OF APPLICANT, ATTO	PRNEY, C	OR AGENT		\dashv
Firm Name Isis Pharmaceuticals, Inc.					
Signature	·		-		一
Printed name Jason D. Ferrone, J.D.	 <u>-</u>				
Date 3/10/2006		Reg. No.	52,887		ᅱ
					${}^{-}$
CERTIFIC	CATE OF TRANSMISS	SION/MAI	ILING	<u>.</u>)
I hereby certify that this correspondence is being facs sufficient postage as first class main an envelope active date shown below:	imile transmitted to the USP ddressed to: Commissioner for	TO or depos or Patents, I	sited with the Ur P.O. Box 1450,	nited States Postal Service wi Alexandria, VA 22313-1450 c	th on
the date shown below: Express IVWW	EV 81400 1191	14			
Yandak	um				
Typed or printed name Pamela Grooms			Date	Bliolous	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

MAR 1 0 2006

PTO/SB/17 (12-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ion Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMR control number Effective on 12/08/2004 Complete if Known Fees pursuant to the Consolidated Appropriations Act. 2005 (H.R. 4818) 10/601,242 Application Number TRANSMI 06/20/2003 Filing Date For FY 2005 Phillip Dan Cook First Named Inventor **Examiner Name** Janet Epps Ford Applicant claims small entity status. See 37 CFR 1.27 **Art Unit** 1635 (\$) 180.00 **TOTAL AMOUNT OF PAYMENT** Attorney Docket No. ISIS-5213 METHOD OF PAYMENT (check all that apply) Credit Card Money Order None Other (please identify): Deposit Account Name: Isis Pharmaceuticals, Inc. Deposit Account Deposit Account Number: 50-0252 For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) X Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee Charge any additional fee(s) or underpayments of fee(s) Credit any overpayments under 37 CFR 1.16 and 1.17 WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. **FEE CALCULATION** 1. BASIC FILING, SEARCH, AND EXAMINATION FEES **FILING FEES** SEARCH FEES **EXAMINATION FEES Small Entity Small Entity** Small Entity **Application Type** Fee (\$) Fee (\$) Fees Paid (\$) Fee (\$) Fee (\$) Fee (\$) Utility 300 150 500 200 250 100 Design 200 100 100 50 130 65 Plant 200 100 300 150 160 80 Reissue 300 150 500 250 600 300 Provisional 200 100 0 0 0 0 2. EXCESS CLAIM FEES **Small Entity** Fee Description Fee (\$) Fee (\$) Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent 50 Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent 100 200 Multiple dependent claims 360 180 **Total Claims Multiple Dependent Claims Extra Claims** Fee (\$) Fee Paid (\$) - 20 or HP = Fee (\$) Fee Paid (\$) HP = highest number of total claims paid for, if greater than 20 Extra Claims Indep. Claims Fee (\$) Fee Paid (\$) - 3 or HP = HP = highest number of independent claims paid for, if greater than 3 3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Total Sheets Number of each additional 50 or fraction thereof Extra Sheets Fee (\$) Fee Paid (\$) _ - 100 = (round up to a whole number) x / 50 = 4. OTHER FEE(S) Fees Paid (\$) Non-English Specification, \$130 fee (no small entity discount) Other: IDS 180.00

SUBMITTED BY

Signature

Registration No. 52,887

Name (Print/Type) Jason D Ferrone, J.D.

Registration No. 52,887

Telephone (760) 931-9200

Date 3/10/2006

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

APPLICATION NUMBER:

10/601,242

FILING DATE:

06/20/2003

FIRST NAMED INVENTOR:

Phillip Dan Cook

ART UNIT:

1635

EXAMINER NAME:

Janet Epps Ford

ATTORNEY DOCKET NUMBER:

ISIS-5213

TITLE: GAPPED 2' MODIFIED OLIGONUCLEOTIDES

I certify that this communication is being deposited with the U.S. Postal Service as Express Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Dated

3/10/06

Pamela Grooms

EV 819 55719411

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT Under 37 C.F.R. §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 C.F. R. §§ 1.56 and 1.97-98, enclosed herewith is PTO Form PTO/SB/08A and PTO/SB/08B listing references for consideration by the Examiner.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

03/14/2006 WABDELR1 00000080 500252 10601242

01 FC:1806

180.00 DA

Serial No.: 10/601,242 Docket No.: ISIS-5213

This Information Disclosure Statement is being filed:
within three months of the filing date of the application, or date of entry
into the national stage of an international application, or before the mailing
date of a first office action on the merits, whichever event last occurred;
before the mailing of a first official action after filing of a request for
continued examination (RCE) under 37 C.F.R. § 1.114;
after three months of the filing date of this national application or the date
of entry of the national stage in an international application, or after the
mailing date of the first official action on the merits, whichever event last
occurred, but before that mailing date of the first office action to occur of
either: (1) a final action under 37 C.F.R. § 1.113; or (2) an action that
otherwise closes prosecution in the application, and:
attached hereto is the fee set forth under 37 C.F.R. § 1.17(p) for
submission of this Information Disclosure Statement under 37 C.F.R. §
1.97(c); OR
Applicant certifies pursuant to 37 C.F.R. § 1.97(e) that:
each item of the information contained in this Information
Disclosure Statement was first cited in a communication from a
foreign patent office in a counterpart foreign application not
more than three months prior to the filing of this Statement;
OR
no item of information contained in this Information
Disclosure Statement was cited in a counterpart foreign
application and, to the knowledge of the person signing this
certification after making reasonable inquiry, no item of
information contained in this Statement was known to any
individual designated under 37 C.F.R. § 1.56(c) more than three
months prior to the filing of this Statement.
on or before the payment of the issue fee but after the mailing date of the
first to occur of either: (1) a final action under 37 C.F.R. § 1.113; (2) a notice
of allowance under 37 C.F.R. § 1.311; or (3) an action that otherwise closes
prosecution in the application, and:
Applicant certifies pursuant to 37 C.F.R. & 1.97(e) that:

Serial No.: 10/601,242 Docket No.: ISIS-5213

each item of infe	ormation contained in this Information
Disclosure Statemen	nt was cited in a communication from a
foreign patent office	e in a counterpart foreign application not
more than three mo	nths prior to the filing of this statement;
OR	
no item of inform	nation contained in this Information
Disclosure Statemen	nt was cited in a counterpart foreign
application and, to t	he knowledge of the person signing this
certification after m	aking reasonable inquiry, no item of
information contain	ed in this Statement was known to any
individual designate	ed under 37 C.F.R. § 1.56(c) more than three
months prior to the	filing of this Statement. AND
attached hereto is the fe	e set forth under 37 C.F.R. § 1.17(p) for
submission of this Informat	ion Disclosure Statement under 37 C.F.R. §
1.97(c); OR	
after the payment of the issue for	ee. Applicant requests that the information
contained in this Information Discl	osure Statement be placed in the file
according to 37 C.F.R. § 1.97(i), al	though the information may not be
considered by the USPTO.	
Enclosed is a copy of each listed refere	nce that may be material to the examination
of this application, and for which there ma	y be a duty to disclose.
☐ This application relies, under 35 U.S.C	. § 120, on the earlier filing date of prior
application No. , filed on , and	I the references cited therein are hereby
referenced, but are not required to be prove	ided in this application under 37 C.F.R. §
1.98(d).	
☐ This application was filed after June 30), 2003. Therefore, pursuant to the waiver of
the requirements under 37 C.F.R. § 1.98(a)	(2)(i), copies of each U.S. Patent and each
U.S. Patent Application Publication are no	t required to be submitted. Copies of any
foreign patent documents and non-patent l	iterature cited herein are enclosed.
☐ Each item of information contained in	this Information Disclosure Statement was
cited in the communication from a foreign	patent office in a counterpart application,
and the communication was not received b	y any individual designated in 37 C.F.R. §

Serial No.: 10/601,242 Docket No.: ISIS-5213

1.56(c) more than thirty days prior to the	ne filing of this	Information	Disclosure
Statement 37 C.F.R. § 1.704(d).			

Applicant submits that no fee is required for the consideration of this Information Disclosure Statement. However, if a fee is due, the Commissioner is hereby authorized to charge Deposit Account No 500252 referencing case number

Consideration of the listed references and favorable action are solicited.

Respectively Submitted,

Dated:/

Jason D. Ferrone, J.D. Registration No.: 52,887

37/0/2006

Isis Pharmaceuticals, Inc. 1896 Rutherford Road Carlsbad, CA 92008

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. EMARITUTE for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

Complete if Known					
Application Number	10/601,242				
Filing Date	06/20/2003				
First Named Inventor	Phillip Dan Cook				
Art Unit	1635				
Examiner Name	Janet Epps Ford				
Attorney Docket Number	ISIS-5213				

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No.1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		,			Figures Appear	
	<u> </u>					
	<u> </u>					
	ļ					

	FOREIGN PATENT DOCUMENTS								
Examiner Cite		Foreign Patent Document	Publication	Nome of Petertee or	Pages, Columns, Lines,				
Initials*	, and the state of	Date Applicant of Cited Document	Date Applicant of Cited Docume	Date Applicant of Cited Document	Date Applicant of Cited Document	Date Applicant of Cited Document		Where Relevant Passages or Relevant Figures Appear	⊥ _e
	161	WO 91/10671	07/25/1991	Isis Pharmaceuticals, Inc.					
	162	WO 92/03568	03/05/1992	Isis Pharmaceuticals, Inc.					
	-								

Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449B/PT()			Complete if Known	
INEO	DRAKION	DIG	CLOCUDE	Application Number	10/601,242	·
		_	CLOSURE	Filing Date	06/20/2003	
SIAI	FMFNIR	ΥA	PPLICANT	First Named Inventor	Phillip Dan Cook	
				Art Unit	1635	
	(Use as many she	eets as	necessary)	Examiner Name	Janet Epps Ford	
Sheet	2	Of	2	Attorney Docket Number	ISIS-5213	

	,	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
	163	Dagle, J.M., et al., "Targeted degradation of mRNA in Xenopus oocytes and embryos directed by modified oligonucleotides: studies of An2 and cyclin in embryogenesis," <i>Nucleic Acids Research</i> , 1990, 18(16), 4751-4757	
	164	Hayase, Y., et al., "Secondary Structure in Formylmethionine tRNA Influences the Site-Directed Cleavage of Ribonuclease H Using Chimeric 2'-O-Methyl Oligodeoxyribonucleotides," <i>Biochemistry</i> , 1990 , <i>29</i> (37), 8793-8797	
	165	Inoue, H., et al., "Studies on the recognition mode of E. coli RNase H using modified oligonucleotide probes," Nucleic Acids Research, 1988, Symposium Series No. 20, 9-10	
	166	Shibahara, S., et al., "Site-directed cleavage of RNA," Nucleic Acids Research, 1987, 15(11), 4403-4415	
	167	Shibahara, S., et al., "Inhibition of human immunodeficiency virus (HIV-1) replication by synthetic oligo-RNA derivatives," <i>Nucleic Acids Research</i> , 1989 , <i>17(1)</i> , 239-252	-
			-

Examiner	Date	-
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.